Risk-based Approaches for Optimizing Treatment in HER2-Positive Early Stage Breast Cancer

Area of Science:

• Oncology
• Medical Oncology
• Breast Cancer Research

Background:

• HER2-positive breast cancer is an aggressive subtype, comprising 15%-20% of all breast cancers.
• Significant advancements in HER2-targeted therapies, including trastuzumab, pertuzumab, neratinib, and ado-trastuzumab emtansine, have improved treatment efficacy.
• The treatment paradigm has shifted towards neoadjuvant therapy for most stage II and III patients due to high response rates and response-adapted adjuvant therapy options.

Purpose of the Study:

• To review the evaluation of patients diagnosed with early-stage HER2-positive breast cancer.
• To provide an evidence- and guideline-based summary of risk-stratified treatment strategies.
• To highlight the importance of multidisciplinary evaluation in optimizing patient care.

Main Methods:

• Review of recent advancements in HER2-targeted therapies.
• Analysis of treatment paradigms, including neoadjuvant and adjuvant therapy approaches.
• Synthesis of evidence and guidelines for risk-based treatment selection.

Main Results:

• New HER2-targeted therapies have been approved for high-risk early-stage disease.
• Neoadjuvant therapy is now standard for most stage II and III HER2-positive breast cancer.
• Treatment de-escalation is possible for some stage I patients due to therapy efficacy.

Conclusions:

• Multidisciplinary evaluation is crucial for optimal management of early-stage HER2-positive breast cancer.
• Future research should focus on tailoring therapy duration and intensity based on disease risk and neoadjuvant response.
• Personalized, risk-adapted treatment strategies are essential for improving outcomes and reducing toxicity.